Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness

NCT03421288 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

677

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer
Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Atezolizumab
DRUG: 5-Fluorouracil
DRUG: Calciumfolinat
DRUG: Oxaliplatin
DRUG: Docetaxel

Sponsor

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Collaborators

[object Object]